Subscribe to Newsletter

Content by Mark Hillen:

Subspecialties Glaucoma

Glaucoma Management Strategies

| Mark Hillen

In many patients, glaucoma cannot be controlled with eyedrops, but a range of surgical techniques and drainage devices can help.

Subspecialties Glaucoma

POAG predisposition

| Mark Hillen

Predictors for primary open-angle glaucoma in a South Indian population.

Subspecialties Retina

Interleukin for a better wet AMD therapy

| Mark Hillen

Subcutaneously-administrated IL-18 works well to reverse choroidal neovascularization (in mice).

Business & Profession Other

Stats on stats

| Mark Hillen

An advanced level of statistical knowledge is necessary to critically appraise most ophthalmology literature.

Business & Profession Imaging & Diagnostics

iPhone eye imaging

| Mark Hillen

More money-saving combinations of smartphones and snap-on adapters that enable you to perform eye examinations on-the-go.

Business & Profession Professional Development

World Travel for a Write up of Your Work

| Mark Hillen

If you’re a retina specialist, you’ll be more likely than not to see patients with diabetic macular edema (DME) on a daily basis. Lasers and anti-VEGF therapy have transformed outcomes within a generation

Subspecialties Cornea / Ocular Surface

Reinventing the Eyedrop: the story of Cationorm

| Mark Hillen

Making an optimal eyedrop formulation has always been a major challenge; compromises had to be made. Nanodroplet emulsion technology has changed that. Here’s how.

Subspecialties Glaucoma

Benchmarking Glaucoma

| Mark Hillen

What does analysis of the last five years of literature on glaucoma tell us about the priorities of the field and the major contributors to it?

Business & Profession Cataract

A Vision Timebomb

| Mark Hillen

Although baby boomers may be in a state of denial regarding their own aging, ophthalmologists know differently. In particular, four diseases of the ageing eye comprise a demographic and economic timebomb.

Business & Profession Professional Development

Business in Brief

| Mark Hillen

Aflibercept gets approved by NICE, STAAR’s Visian ICL with CentraFLOW gets approved in Japan, and rises and falls in Allergan and Alcon’s revenues.

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: